Medicinal cannabis company Australian Natural Therapeutics Group (ANTG) has announced a strategic partnership with New Zealand’s largest medicinal cannabis distributor, NUBU Pharmaceuticals.
In an Australian-first, the agreement will see locally cultivated and dried medicinal cannabis flower shipped to New Zealand in the second half of the year, with oils to follow.
ANTG Chief Executive Officer, Matthew Cantelo, says the new agreement is a coup for both countries, cementing the mutually beneficial Trans-Tasmanian relationship.
Mr Cantelo says ANTG will be the first Australian cannabis flower imported into New Zealand, and potentially, the first company to legally sell flower in New Zealand.
“NUBU has spent the last five years building a distribution network that now reaches every pharmacy in New Zealand,” he says.
Established in 2015, ANTG produces four strains of medicinal cannabis flower and is now producing four oil combinations.
Gold standard in growing
ANTG partners with research organisations including CSIRO, University of Newcastle and University of Western Sydney, to unlock the potential of cannabis in the fight against cancer, dementia and inflammation.
ANTG’s growing and manufacturing facility complies with international quality standards (GACP and GMP), securing the gold standard in growing and manufacturing medicinal cannabis.
ANTG products will be made available to Australian patients as a priority, said Mr Cantelo.
Medical cannabis has strong evidence to support its use in treating cancer-related pain.
And Australia is currently conducting trials into medicinal cannabis for the treatment of chronic pain.
GPs report that patients presenting with chronic pain have increased by 65% in the past decade.
New export markets
Given the health and addiction risk factors associated with many pharmaceutical pain killers, such as opioids, doctors and patients are seeking information on how medical cannabis may help in reducing chronic pain.
Mark Dye, CEO of NUBU Pharmaceuticals, welcomed the ANTG agreement adding that it will be mutually beneficial for both countries.
“ANTG are very much leading the Australasian cannabis industry. We are over the moon to have them as a distribution partner and an investor and can’t wait to make ANTG product available to patients locally,” said Mr Dye.
ANTG has listed three medicinal cannabis flower products on the Australian Register of Therapeutic Goods (ARTG).
Listing on the ARTG means ANTG products can be lawfully exported from Australia to overseas patients.
The company reports its dried THC cannabis flowers will soon be exported to the European Union.
ANTG recently announced a $93 million nine-year deal to export to Germany and is looking to further expand into the Canadian market.